Nanna Lüneborg, PhD, MBA, General Partner, will participate as a panellist at the ABI Conference Sweden 2026, taking place 24–26 September in Stockholm, Sweden.
On 25 September, Nanna will join the panel “What Makes Biotech Worth Backing?” alongside Nina Rawal of We Venture Capital and Peter Svennilson of The Column Group. The discussion will be moderated by Mårten Steen of HealthCap.
The conference brings together leaders from across the global biopharmaceutical and investment communities for a programme of panel discussions, fireside chats, and scientific presentations exploring the latest developments in biotechnology, drug development, and healthcare innovation.
The ABI Conference provides a forum to exchange perspectives with investors, industry leaders, and scientific innovators on the opportunities shaping the future of biotech and the investment landscape.